← all works
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Oncology
- Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Field
- Medicine
- Canadian institutions
- University of TorontoPrincess Margaret Cancer Centre
- Funders
- Merck
- Keywords
- MedicinePembrolizumabSorafenibInternal medicineClinical endpointHepatocellular carcinomaAdverse effectResponse Evaluation Criteria in Solid TumorsPopulationOncologyDiscontinuationClinical trialPhases of clinical researchSurgeryCancerImmunotherapy
- Has abstract in OpenAlex
- no